PTPN11 and neoplasm: Accordingly, several Shp2 pharmacological inhibitors are being developed for cancer therapy54 including a promising allosteric inhibitor that exhibits high specificity and capacity to suppress proliferation in RTK-driven human cancer cells and mouse tumor xenograft models55.